|Friday, February 21|
|CS12 Graphics in Oncology Drug Development||
Fri, Feb 21, 1:30 PM - 3:00 PM
Statistical Graphics in GSK Oncology Drug Development: Our Road to Advanced Graphic Capabilities and Insight (302756)*Michael Gabriel Durante, GlaxoSmithKline
Keywords: GSK, Oncology, GlaxoSmithKline, Graphics, Michael Durante
The primary goal of this presentation will be to highlight the role statistical graphics has played within oncology drug development at GSK over the years. Graphics often play a key role in the data review and drug approval process, from helping to identify, isolate, and explain potential safety signals to highlighting potential trends in efficacy. Graphical approaches at the patient, subgroup, study, and cross-study levels will be shared. The foundations of the history and development of our strong graphics culture and standard software advances will be discussed. A handful of recent examples of complex, multi-level graphics that have had a real effect on drug development also will be highlighted. These will include an example of a hybrid graphic that played a major role in investigating the potential patterns in survival, and progression-free survival data for a recent approval will be shared. Additionally, an example that provided a high-level picture of the longitudinal safety signals for a particular subgroup of patients in a recently submitted study also will be shared.